Anne Hathaway, the acclaimed actress, is poised for a major cinematic comeback in 2026. After a period of focusing on family and personal growth, Hathaway is set to star in three diverse films: "Mother Mary," "The Devil Wears Prada 2," and "The Odyssey." This resurgence marks a conscious decision to re-engage with high-profile projects, showcasing her mature artistic and personal readiness for the spotlight.

Amidst global uncertainties, a strategic investment in the Schwab U.S. Dividend Equity ETF is highlighted as a prudent choice. This ETF focuses on high-yielding dividend stocks, offering stability and income. Its diverse portfolio includes sectors like energy and defense, positioning it well to navigate market fluctuations and geopolitical tensions, making it an attractive option for long-term investors seeking both resilience and growth.

Despite significant price fluctuations in the first quarter of this year, electric vehicle giant Tesla has maintained its substantial Bitcoin holdings. The company continues to possess 11,509 BTC, valued at approximately $895 million, as revealed in its latest financial disclosures. This steadfast approach comes even as Bitcoin experienced a notable decline, resulting in an impairment loss for Tesla. The firm's long-term commitment to the cryptocurrency, initiated in 2021, remains a key aspect of its financial strategy, underscoring a belief in the digital asset's enduring value.

Baker Hughes (NASDAQ: BKR) is set to release its first-quarter earnings report on Thursday, April 23. Analysts anticipate a slight decrease in earnings per share to 49 cents from 51 cents in the previous year, with revenue projected at $6.33 billion. The company recently agreed to sell its Waygate Technologies business to Hexagon (OTC: HXGBY) for approximately $1.45 billion. Several analysts have updated their ratings and price targets for Baker Hughes ahead of the earnings call.

White Brook Capital Partners' Q1 2026 investor letter highlights ICON Public Limited Company (ICLR) as a potentially undervalued stock. Despite a recent revenue recognition investigation that caused a significant stock drop, the clinical research organization maintains strong fundamentals, a substantial backlog, and favorable positioning in high-growth therapeutic areas like oncology and GLP-1/obesity. The firm believes ICLR's current valuation significantly underestimates its business strength and anticipates a rally once financial clarity is re-established.